|
|
|
|
|
|
|
|
|
09.03.26 - 19:24
|
Veolia Posts Strong Yearly Results, Advancing Environmental Security in the U.S. (Business Wire)
|
|
|
> North America's 3.6% organic revenue growth in 2025 and $5.3 billion in revenue, including Water Technologies, are key contributors to Veolia's global $50.11 billion revenue
> The successful execution of Veolia's GreenUp program in 2025 met or exceeded all financial targets, setting precedent for 2026 goals while expanding growth boosters: hazardous waste capacity, water treatment services / technologies and PFAS management in North America
> Four 2025 acquisitions in the hazardous waste booster, including a major one to create a national platform, accelerated growth in this critical service for industrial expansion in the U.S.
> Veolia continued to develop its PFAS treatment capabilities and strengthen its position as a leader in water and water technologies in the U.S.BOSTON--(BUSINESS WIRE)--#earnings--Veolia, the world leader in environmental services, released powerful 2025 financial results that demonstrated the success of its GreenUp growth strategy, fostering environmental security by meeting...
|
|
|
|
|
09.03.26 - 18:57
|
Precision Aviation Services, a subsidiary of Precision Aviation Group, Named Authorized Autopilot Installer for Thales and StandardAero StableLight™ System Ahead of Verticon 2026 (PR Newswire)
|
|
|
ATLANTA, March 9, 2026 /PRNewswire/ -- Precision Aviation Services, a subsidiary of Precision Aviation Group, Inc. (PAG), a leading provider of maintenance, repair, and overhaul (MRO) and value-added services for the aerospace and defense industries, today announced it has been approved......
|
|
|
|
|
|
|
|
|
09.03.26 - 18:39
|
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma (GlobeNewswire EN)
|
|
|
PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen's decision to withdraw is based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial (evaluating tazemetostat in combination with lenalidomide plus rituximab (R2) vs R2 in follicular lymphoma). The Independent Data Monitoring Committee (IDMC) advised that, based on adverse events of secondary hematologic malignancies, the risks may outweigh potential benefits for patients within this treatment regimen. As a result of these data, Ipsen is withdrawing Tazverik effective immediately, including both for follicular lymphoma (FL) and epithelioid sarcoma (ES)....
|
|
|
|
|
|
|
|
|
|
|
|
|
09.03.26 - 18:03
|
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 9, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted ODD to NTZ (nitazoxanide), its investigational small-molecule drug candidate developed as a new formulation for the treatment of Acute-on-Chronic Liver Failure (ACLF)....
|
|
|
|
|
|
|
|
|
|
Alle News zu Frankreich 8030.9505 0.0% (CAC 40 Kurs)
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
